Market Overview:
The global liver diseases therapeutics drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of liver diseases, rising awareness about available treatments, and growing demand for better-quality therapies. The global liver diseases therapeutics drugs market is segmented on the basis of type into oral liver diseases therapeutics drugs and injection liver diseases therapeutics drugs. The oral segment is expected to account for a larger share of the market in 2018 owing to its high prevalence and growing demand for better-quality therapies. By application, the hospitals segment is expected to account for a larger share of the market in 2018 due to increased access to healthcare facilities and rising awareness about available treatments.
Product Definition:
Liver Diseases Therapeutics Drugs are a class of drugs that are used to treat diseases of the liver. They can help to improve liver function, reduce inflammation, and fight infection. The importance of Liver Diseases Therapeutics Drugs is that they can help to improve the health of the liver and reduce the symptoms associated with liver disease.
Oral Liver Diseases Therapeutics Drugs:
Liver diseases therapeutics drugs market is expected to witness significant growth over the forecast period owing to increasing prevalence of liver diseases and growing R&D initiatives by pharmaceutical companies. According to data published in NCBI, around 1.0% of deaths worldwide occur due to liver cancer or cirrhosis every year.
Injection Liver Diseases Therapeutics Drugs:
Injection liver diseases therapeutics drugs are used for treatment of certain liver disorders. Some of the most common indications for which these drugs are prescribed include chronic hepatitis, bile duct obstruction, and intrahepatic cholestasis. The high prevalence rate of such conditions has led to an increased demand for effective therapeutic options and this is expected to drive market growth over the forecast period.
Application Insights:
Based on the application, the global liver diseases therapeutics drugs market is segmented into hospitals, clinics and other. Hospitals held the largest share in 2017 owing to factors such as a large patient base and presence of dedicated liver disease treatment facilities. The hospital segment is anticipated to maintain its dominance over the forecast period due to high usage of injection therapies for various liver disorders in hospitals.
The clinics application segment was valued at USD 536.3 million in 2017 owing to increasing prevalence of chronic conditions that require long-term management along with rising geriatric population across globe who are susceptible to develop various health issues including alcoholic and non-alcoholic fatty liver diseases which eventually requires medical consultation regarding diagnosis & treatment options. This trend is expected drive growth over next few years especially during upcoming COVID-19 pandemic where people will be referred by their general physicians for early diagnosis & efficient management procedures thus contributing towards revenue growth during forecast period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of hepatocellular carcinoma and other liver diseases, rising adoption of new therapies, and high healthcare expenditure. In addition, favorable reimbursement policies for new treatment options are also expected to drive growth in this region. Asia Pacific is estimated to be the fastest-growing regional market from 2018 to 2030 owing to improving economic conditions and growing patient awareness levels regarding available treatment options for liver diseases.
Growth Factors:
- Increasing incidence of liver diseases due to changing lifestyles and environmental factors.
- Growing awareness about the available treatment options for liver diseases.
- Rising demand for better and more effective therapies for treating liver diseases.
- increasing investment by pharmaceutical companies in research and development of new drugs for the treatment of liver diseases .
Scope Of The Report
Report Attributes
Report Details
Report Title
Liver Diseases Therapeutics Drugs Market Research Report
By Type
Oral Liver Diseases Therapeutics Drugs, Injection Liver Diseases Therapeutics Drugs
By Application
Hospitals, Clinics, Other
By Companies
F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Achillion Pharmaceuticals, AbbVie, Angion Biomedica, Bayer, LG Life Sciences, F. Hoffmann-La Roche, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, Verva Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
123
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Liver Diseases Therapeutics Drugs Market Report Segments:
The global Liver Diseases Therapeutics Drugs market is segmented on the basis of:
Types
Oral Liver Diseases Therapeutics Drugs, Injection Liver Diseases Therapeutics Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Achillion Pharmaceuticals
- AbbVie
- Angion Biomedica
- Bayer
- LG Life Sciences
- F. Hoffmann-La Roche
- ProMetic Life Sciences
- Raptor Pharmaceuticals
- Shenzhen Kangtai Biological Products
- Verva Pharmaceuticals
Highlights of The Liver Diseases Therapeutics Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Liver Diseases Therapeutics Drugs
- Injection Liver Diseases Therapeutics Drugs
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Liver Diseases Therapeutics Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Liver diseases therapeutics drugs are medications used to treat liver diseases.
Some of the major companies in the liver diseases therapeutics drugs market are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Achillion Pharmaceuticals, AbbVie, Angion Biomedica, Bayer, LG Life Sciences, F. Hoffmann-La Roche, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, Verva Pharmaceuticals.
The liver diseases therapeutics drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Liver Diseases Therapeutics Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Liver Diseases Therapeutics Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Liver Diseases Therapeutics Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Liver Diseases Therapeutics Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Liver Diseases Therapeutics Drugs Market Size & Forecast, 2020-2028
4.5.1 Liver Diseases Therapeutics Drugs Market Size and Y-o-Y Growth
4.5.2 Liver Diseases Therapeutics Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Oral Liver Diseases Therapeutics Drugs
5.2.2 Injection Liver Diseases Therapeutics Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Liver Diseases Therapeutics Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Liver Diseases Therapeutics Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Oral Liver Diseases Therapeutics Drugs
9.6.2 Injection Liver Diseases Therapeutics Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Oral Liver Diseases Therapeutics Drugs
10.6.2 Injection Liver Diseases Therapeutics Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Oral Liver Diseases Therapeutics Drugs
11.6.2 Injection Liver Diseases Therapeutics Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Oral Liver Diseases Therapeutics Drugs
12.6.2 Injection Liver Diseases Therapeutics Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Oral Liver Diseases Therapeutics Drugs
13.6.2 Injection Liver Diseases Therapeutics Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Liver Diseases Therapeutics Drugs Market: Competitive Dashboard
14.2 Global Liver Diseases Therapeutics Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 F. Hoffmann-La Roche
14.3.2 Gilead Sciences
14.3.3 GlaxoSmithKline
14.3.4 Johnson & Johnson
14.3.5 Merck
14.3.6 Achillion Pharmaceuticals
14.3.7 AbbVie
14.3.8 Angion Biomedica
14.3.9 Bayer
14.3.10 LG Life Sciences
14.3.11 F. Hoffmann-La Roche
14.3.12 ProMetic Life Sciences
14.3.13 Raptor Pharmaceuticals
14.3.14 Shenzhen Kangtai Biological Products
14.3.15 Verva Pharmaceuticals
